Navigation Links
Cannabis Science Initiates Scientific Cultivation Programs to Test Multiple Strains of Cannabis to Obtain Extract Formulations for Clinical Drug Development Targeting Multiple Critical Ailments Starting with Cancer and Neurological Disorders
Date:7/31/2014

COLORADO SPRINGS, Colo., July 31, 2014 /PRNewswire/ -- Cannabis Science, Inc. (OTC-QB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce that it has commenced production of multiple strains of cannabis and European Union certified hemp varieties to initiate scientific research to select the best strains for development of proprietary formulations for clinical drug development to bring the cannabis formulations to market for critical ailments such as cancer and neurological disorders.

Mr. Mario S. Lap, Director and President of European Operations, stated, "Cannabis Science intends to leverage its team's expertise to create a framework for research and clinical testing. We are excited to report further development and progress as we proceed forward."

The facilities are located in the Alicante region of Spain, and the Company is working with a local partner to initiate an agricultural program, to prepare GMP production and to start building the research framework to conduct scientific testing of extracts and the active constituents contained in the cannabis plant with the objective of developing selected formulations for clinical use.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science, Inc.
Dr. Dorothy Bray, CEO & Director
www.cannabisscience.com
dorothy.bray@cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658

Investment Inquiries
Robert Kane, CFO & Director
robert.kane@cannabisscience.com
Tel: 1.561.420.4824

Raymond C. Dabney, Management Consultant, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788


'/>"/>
SOURCE Cannabis Science, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Rapid Fire Marketing: CANNAcig to Sponsor Medical Cannabis Cup 2012 in San Francisco
2. Cannabis Science Gets Set to Release "Phytiva" Its Newest Brand of Over-the-Counter Skin and Nutraceutical Product Lines Through its Newest Venture Phytiva Pharmaceuticals Inc.
3. Cannabis Science Provides Corporate Guidance on Preclinical Initiatives and Recent Corporate Developments for its Shareholders; CBIS Announces plans for 1st Q of 2013 Webinar Investor Call
4. Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Sciences Approach to Development of CS-TATI-1 to Inhibit Kaposi Sarcoma
5. New Study Shows Cannabis Effects on Driving Skills
6. Optimism of Cannabis Patients Creates More Demand for Phytiva Brand of Cannabinoid Solutions as Illinois and New Hampshire Take Key Legislative Steps Toward Legalization of Medical Cannabis
7. Abattis Provides $10,000 Sponsorship to the American Herbal Pharmacopoeia for Cannabis Monograph Project
8. Cannabis Science announces preclinical development program for CS-TATI-I, commencing EU operations in the Netherlands and sourcing proprietary material for pharmacokinetic characterization
9. Virogen Announces Launch of New Business Unit, "The Cannabis Connection", and Sets Sights on $15-20 Billion Legal Marijuana Market
10. Virogens New Business Unit, "The Cannabis Connection," to Focus on High-End Medicinal Marijuana Dispensary Niche within $15-20 Billion Legal Marijuana Market
11. Cannabis Science Appoints Clinical Development Expert, Dr. Dorothy Bray, as Chief Executive Officer (CEO) and Director, Focusing on CS-TATI-1 and Building Companys Drug Development Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... -- Glycotope GmbH, a clinical-stage immuno-oncology company ... of Dr. Alfredo Zurlo as Chief Medical ... many years clinical experience and a proven track record ... was at Mologen AG where he was Chief Medical ... Zurlo held various positions at F Hoffmann La Roche ...
(Date:4/28/2016)... , April 28, 2016  While Abbott,s ... complement the company,s valve repair and stent business, ... also places Abbott more firmly into patient monitoring.  ... the fastest growing device areas, with double-digit growth ... recent report,  Advanced Remote Patient Monitoring ...
(Date:4/28/2016)... April 28, 2016 ... George Phillips und Stephen Schmidt ... ArisGlobal®, ein führender Anbieter cloudbasierter ... heute bekannt, dass neue Führungskräfte zum Team ... sind, die vielfältige Erfahrungen mitbringen.  Dies wird ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... Coast Dental Fort Stewart is celebrating its ... location in the Exchange Furniture Mall at 112 Vilseck Road in Fort Stewart. There ... TV. Plus attendees will have the opportunity to meet general dentists Thomas Richards, DDS, ...
(Date:4/29/2016)... Kansas City, Missouri (PRWEB) , ... April 29, 2016 , ... ... Unlike traditional crutches which put pressure on the armpits, the M+D Crutch evenly distributes ... less strain on their wrists and hands when using the crutches than with other ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Robert Mondavi, one of the ... Cosmetic dentistry is a fast-growing field as more patients are discovering the many different ... more about the options currently available to them and which ones might work for ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the market ... funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... and accelerate its technology and product roadmap. , “Jvion is experiencing ...
(Date:4/29/2016)... ... 2016 , ... The infertility specialists at HRC Fertility/Orange County (HRC/OC) -- Dr. ... Potter -- are proud of the recent release of their 2014 in vitro fertilization ... published the latest verified data for 375 U.S. member clinics. *Preliminary data shows ...
Breaking Medicine News(10 mins):